Fortis Healthcare FY26 Annual Earnings Summary
3 quarters covered · ₹6,763 Cr revenue · ₹793 Cr PAT · 23.1% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q1 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY26Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY26Risks flagged during the year
Gleneagles revenue declined 4% in 9M due to clinician attrition and management changes; turnaround uncertain.
Q1 FY26 · mediumAnalyst raised concern that Gleneagles facilities have historically low margins (~3-4%), and the 3% fee may not capture full upside from operational improvements.
Q1 FY26 · mediumNew bed additions (e.g., Manesar, FMRI) may take time to reach optimal occupancy, delaying margin contribution.
Q2 FY26 · mediumManagement expressed caution on CGHS due to non-predictability of payments and potential circular changes, despite recent rate increases.
Q2 FY26 · mediumThe O&M arrangement for five hospitals may face operational challenges; future conversion to ownership is uncertain.
Q3 FY26 · mediumManagement noted intense competition in Hyderabad, making M&A there less attractive.
Q1 FY26 · lowDespite margin improvement, diagnostics revenue growth of 7.4% remains modest; management expects only gradual acceleration to double-digits.
Q2 FY26 · lowNet debt rose to INR 2,219 crore (0.96x EBITDA) from 0.16x a year ago due to acquisitions, though management is comfortable.
Q2 FY26 · lowCommissioning of 225 beds at SMRI delayed by three months to March 2026, pushing revenue contribution to next fiscal.
Q3 FY26 · lowNew facilities like Greater Noida and Adayu dragged overall occupancy by ~50 bps.
What changed through the year
Q1 FY26 · Hospital EBITDA margin improvement of ~200 bps for FY26
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
Q1 FY26 · Diagnostics EBITDA margin of 22-23% for FY26
Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.
Q1 FY26 · Add ~900 beds in FY26, ~50% operationalized this year
Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
Q1 FY26 · Diagnostics revenue growth to reach low double-digits in 6-8 quarters
Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.
Q2 FY26 · Hospital EBITDA margin to exceed initial guidance of 20.5-22.5%
Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.
Q2 FY26 · Organic bed addition of 400-500 beds in FY26
Company added 550 operational beds in H1 FY26 and expects full-year addition of 400-500 beds.
Q2 FY26 · Diagnostics EBITDA margin of 23-24% for full year FY26
Agilus CFO guided margins to be around 23-24% for the full year, based on H1 performance of 24%.
Q2 FY26 · ARPOB growth of 5-6% in H2 FY26
Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.
Q3 FY26 · Brownfield bed addition of 400+ beds in FY27
Targeting over 400 brownfield beds next year, primarily from FMRI expansion (200 beds) and other facilities.
Q3 FY26 · ARPOB growth of 4-5% expected for next two years
Management expects ARPOB to grow 4-5% annually, driven by case mix and price increases.
Q3 FY26 · IHH equity infusion likely in 3-6 months
IHH may infuse fresh equity via preferential allotment to strengthen balance sheet for growth.